These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 445500)

  • 1. Melphalan in metastatic cancer of the prostate: a pilot study.
    Franks CR
    Cancer Treat Rep; 1979 Feb; 63(2):228-9. PubMed ID: 445500
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report.
    Kvols LK; Eagan RT; Myers RP
    Cancer Treat Rep; 1977; 61(2):311-2. PubMed ID: 326400
    [No Abstract]   [Full Text] [Related]  

  • 3. Melphalan in metastatic cancer of the prostate.
    Franks CR
    Cancer Treat Rev; 1979 Jun; 6 Suppl():121-5. PubMed ID: 498165
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial.
    Moore MR; Troner MB; DeSimone P; Birch R; Irwin L
    Cancer Treat Rep; 1986 Apr; 70(4):541-2. PubMed ID: 3698053
    [No Abstract]   [Full Text] [Related]  

  • 5. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 6. Melphalan in advanced prostatic cancer: a pilot study.
    Houghton AL; Robinson MR; Smith PH
    Cancer Treat Rep; 1977 Aug; 61(5):923-4. PubMed ID: 890698
    [No Abstract]   [Full Text] [Related]  

  • 7. [Ketoconazole in the treatment of advanced cancer of the prostate: experience with 14 patients].
    Castillo Cádiz O; Martínez Sanz P
    Rev Med Chil; 1985 Apr; 113(4):309-11. PubMed ID: 3835638
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of estrogen therapy on metastatic carcinoma of the prostate.
    Anikwe RM
    Int Surg; 1977 Oct; 62(10):532-6. PubMed ID: 591215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of spirogermanium in metastatic prostate cancer.
    Dexeus FH; Logothetis C; Samuels ML; Hossan B
    Cancer Treat Rep; 1986 Sep; 70(9):1129-30. PubMed ID: 3742495
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostatic acid phosphatase and prostate-specific antigen in prostate cancer.
    Kuriyama M; Loor R; Wang MC; Lee C; Killian CS; Papsidero LD; Inaji H; Nishiura T; Slack NH; Murphy GP; Chu TM
    Int Adv Surg Oncol; 1982; 5():29-49. PubMed ID: 6178696
    [No Abstract]   [Full Text] [Related]  

  • 11. European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer.
    Jones WG; Fosså SD; Bono AV; Klijn JG; De Pauw M; Sylvester R
    Cancer Treat Rep; 1987 Dec; 71(12):1317-8. PubMed ID: 3480046
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II evaluation of mitoguazone in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group trial.
    Moore MR; Graham SD; Birch R; Irwin L
    Cancer Treat Rep; 1987 Jan; 71(1):89-90. PubMed ID: 3791273
    [No Abstract]   [Full Text] [Related]  

  • 13. [Tumor markers of prostate cancer--evaluation of serum PAP and PA].
    Miki M
    Gan No Rinsho; 1985 May; 31(6 Suppl):664-9. PubMed ID: 2411965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination cytostatic chemotherapy of advanced metastatic cancer of the prostate. A preliminary uncontrolled study].
    Ogaard S; Jensen TS
    Ugeskr Laeger; 1977 Feb; 139(9):515-7. PubMed ID: 841743
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer.
    Mougenot P; Bressolle F; Culine S; Solassol I; Poujol S; Pinguet F
    Anticancer Res; 2006; 26(3B):2197-203. PubMed ID: 16821586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostatic acid phosphatase immunoperoxidase staining of cytologically positive effusions associated with adenocarcinomas of the prostate and neoplasms of undetermined origin.
    Broghamer WL; Richardson ME; Faurest S; Parker JE
    Acta Cytol; 1985; 29(3):274-8. PubMed ID: 3890441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acid phosphatase, alkaline phosphatase and prostate-specific antigen--usefulness in the diagnosis of metastatic disease and follow-up.
    Bauer HW
    Prog Clin Biol Res; 1988; 269():33-42. PubMed ID: 2455908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
    Bui NB; Chauvergne J; Brunet R; Richaud P; Hoerni B; Lagarde C; Le Guillou M
    Bull Cancer; 1986; 73(1):65-7. PubMed ID: 3779124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The diagnostic value of serum acid phosphatases in carcinoma of the prostate (author's transl)].
    Braun JS; Habig H; Crüsemann D
    Urologe A; 1974 Sep; 13(5):236-41. PubMed ID: 4138057
    [No Abstract]   [Full Text] [Related]  

  • 20. [Personal reflections on cancer of the prostate].
    Wojewski A
    J Urol Nephrol (Paris); 1968 Jun; 74(6):451-60. PubMed ID: 4300445
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.